Novartis AG (NVS): Price and Financial Metrics


Novartis AG (NVS): $92.71

0.44 (+0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NVS POWR Grades


  • NVS scores best on the Stability dimension, with a Stability rank ahead of 98.75% of US stocks.
  • NVS's strongest trending metric is Stability; it's been moving up over the last 31 weeks.
  • NVS ranks lowest in Momentum; there it ranks in the 11th percentile.

NVS Stock Summary

  • With a market capitalization of $205,533,950,110, Novartis Ag has a greater market value than 98.98% of US stocks.
  • With a one year PEG ratio of 127.64, Novartis Ag is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 78.96% of US stocks.
  • In terms of volatility of its share price, NVS is more volatile than merely 1.14% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novartis Ag are TMO, NVO, ABT, MRK, and CVX.
  • Visit NVS's SEC page to see the company's official filings. To visit the company's web site, go to www.novartis.com.

NVS Valuation Summary

  • NVS's price/sales ratio is 4; this is 11.11% higher than that of the median Healthcare stock.
  • NVS's price/sales ratio has moved down 0.6 over the prior 243 months.
  • NVS's EV/EBIT ratio has moved up 2.2 over the prior 243 months.

Below are key valuation metrics over time for NVS.

Stock Date P/S P/B P/E EV/EBIT
NVS 2021-06-29 4.1 4.1 25.9 22.8
NVS 2020-09-02 4.1 3.8 28.2 23.3
NVS 2019-02-14 3.9 2.6 16.3 15.2
NVS 2014-10-21 3.7 3.1 22.0 19.0
NVS 2008-03-12 2.8 2.2 9.2 8.4
NVS 2006-01-23 4.8 4.0 23.5 19.7

NVS Stock Price Chart Interactive Chart >

Price chart for NVS

NVS Price/Volume Stats

Current price $92.71 52-week high $98.52
Prev. close $92.27 52-week low $77.04
Day low $92.09 Volume 2,471,800
Day high $92.71 Avg. volume 1,885,719
50-day MA $91.51 Dividend yield 2.25%
200-day MA $89.14 Market Cap 212.19B

Novartis AG (NVS) Company Bio


Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.

NVS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$92.71$37.01 -58%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novartis Ag. To summarize, we found that Novartis Ag ranked in the 32th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Novartis Ag, consider:

  • In the past 5.77 years, Novartis Ag has a compound free cash flow growth rate of 0%; that's higher than only 20.02% of free cash flow generating stocks in the Healthcare sector.
  • Novartis Ag's weighted average cost of capital (WACC) is 9%; for context, that number is higher than only 23.99% of tickers in our DCF set.
  • NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than only 23.99% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-59%
1%-58%
2%-58%
3%-58%
4%-57%
5%-57%

Want more companies with a valuation profile/forecast similar to that of Novartis Ag? See GMED, NRC, CRL, DHR, and DXCM.


NVS Latest News Stream


Event/Time News Detail
Loading, please wait...

NVS Latest Social Stream


Loading social stream, please wait...

View Full NVS Social Stream

Latest NVS News From Around the Web

Below are the latest news stories about Novartis Ag that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development and commercialization, continues to advance in the clinic as the potential first-in-class treatment for lipoprotein(a) or Lp(a)-driven cardiovascular disease. The Novartis pivotal Phase 3 cardiovascular outcomes study of pelacarsen, Lp(a) HORIZON (NCT04023552), has reached 50% enrollment with a target goal of 7,68

Yahoo | August 2, 2021

Together Against Child Mortality: Novartis and Save the Children Launch Health Project in the Slums of Nairobi

BASEL, SWITZERLAND, August 2, 2021 /3BL Media/ - Novartis and children’s rights organization Save the Children are launching their first common health project tackling child mortality in Kenya's Ki...

Yahoo | August 2, 2021

Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.

Yahoo | July 28, 2021

Glaxo (GSK) Beats Earnings and Revenues Estimates in Q2

Glaxo (GSK) beats earnings as well as revenues estimates in the second quarter of 2021. Stock up.

Yahoo | July 28, 2021

Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio

Once considered undruggable, the phosphatase enzyme SHP2 has seen recent interest from a suite of Big Pharmas, including AstraZeneca, Amgen, Novartis and Merck. Now Bristol Myers Squibb is getting in on the action, with a deal to pair its PD-1 superstar Opdivo with BridgeBios SHP2 inhibitor for difficult-to-treat cancers. BMS

Endpoints News | July 27, 2021

Read More 'NVS' Stories Here

NVS Price Returns

1-mo N/A
3-mo 6.14%
6-mo 4.90%
1-year 12.85%
3-year 35.35%
5-year 44.97%
YTD 0.57%
2020 2.08%
2019 28.03%
2018 5.95%
2017 18.80%
2016 -12.56%

NVS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVS Dividend History

Continue Researching NVS

Want to see what other sources are saying about Novartis Ag's financials and stock price? Try the links below:

Novartis Ag (NVS) Stock Price | Nasdaq
Novartis Ag (NVS) Stock Quote, History and News - Yahoo Finance
Novartis Ag (NVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8116 seconds.